1. Delellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumours of endocrine organs. 3rd ed. Lyon: International Agency for Research on Cancer (IARC); 2004. p. 49-123.
2. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 65-143.
3. Williams ED. Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 2000;8:181-3.
[CROSSREF] [PUBMED]
4. Carney JA, Hirokawa M, Lloyd RV, Papotti M, Sebo TJ. Hyalinizing trabecular tumors of the thyroid gland are almost all benign. Am J Surg Pathol 2008;32:1877-89.
[CROSSREF] [PUBMED]
5. Kakudo K, Bai Y, Liu Z, Li Y, Ito Y, Ozaki T. Classification of thyroid follicular cell tumors: with special reference to borderline lesions. Endocr J 2012;59:1-12.
[CROSSREF] [PUBMED]
6. Kakudo K, Bai Y, Liu Z, Ozaki T. Encapsulated papillary thyroid carcinoma, follicular variant: a misnomer. Pathol Int 2012;62:155-60.
[CROSSREF] [PUBMED]
7. Kakudo K, El-Naggar AK, Hodak SP, Khanafshar E, Nikiforov YE, Nose V, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in thyroid tumor classification. Pathol Int 2018;68:327-33.
[CROSSREF] [PUBMED]
8. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016;2:1023-9.
[CROSSREF] [PUBMED] [PMC]
9. Baloch ZW, Seethala RR, Faquin WC, Papotti MG, Basolo F, Fadda G, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathol 2016;124:616-20.
[CROSSREF] [PUBMED]
10. Bychkov A, Hirokawa M, Jung CK, Liu Z, Zhu Y, Hong SW, et al. Low rate of noninvasive follicular thyroid neoplasm with papillary-like nuclear features in Asian practice. Thyroid 2017;27:983-4.
[CROSSREF] [PUBMED]
11. Bychkov A, Keelawat S, Agarwal S, Jain D, Jung CK, Hong S, et al. Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries. Pathology 2018;50:411-7.
[CROSSREF] [PUBMED]
12. Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol 2017;30:810-25.
[CROSSREF] [PUBMED]
13. Akaishi J, Kondo T, Sugino K, Ogimi Y, Masaki C, Hames KY, et al. Prognostic impact of the turin criteria in poorly differentiated thyroid carcinoma. World J Surg 2019;43:2235-44.
[CROSSREF] [PUBMED]
14. Ibrahim AA, Wu HH. Fine-needle aspiration cytology of noninvasive follicular variant of papillary thyroid carcinoma is cytomorphologically distinct from the invasive counterpart. Am J Clin Pathol 2016;146:373-7.
[CROSSREF] [PUBMED]
15. Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, Basolo F, et al. Cytological features of “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology. Hum Pathol 2016;54:134-42.
[CROSSREF] [PUBMED]
16. Parente DN, Kluijfhout WP, Bongers PJ, Verzijl R, Devon KM, Rotstein LE, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: is NIFTP truly benign? World J Surg 2018;42:321-6.
[CROSSREF] [PUBMED]
17. Rosario PW, Mourao GF. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a review for clinicians. Endocr Relat Cancer 2019;26:R259-66.
[CROSSREF] [PUBMED]
18. Seethala RR, Baloch ZW, Barletta JA, Khanafshar E, Mete O, Sadow PM, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. Mod Pathol 2018;31:39-55.
[CROSSREF] [PUBMED]
19. Strickland KC, Vivero M, Jo VY, Lowe AC, Hollowell M, Qian X, et al. Preoperative cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a prospective analysis. Thyroid 2016;26:1466-71.
[CROSSREF] [PUBMED]
20. Thompson LD. Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: a name change to noninvasive follicular thyroid neoplasm with papillary-like nuclear features would help prevent overtreatment. Mod Pathol 2016;29:698-707.
[CROSSREF] [PUBMED]
21. Thompson LD, Poller DN, Kakudo K, Burchette R, Nikiforov YE, Seethala RR. An international interobserver variability reporting of the nuclear scoring criteria to diagnose noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a validation study. Endocr Pathol 2018;29:242-9.
[CROSSREF] [PUBMED]
22. Yang GC, Fried KO, Scognamiglio T. Sonographic and cytologic differences of NIFTP from infiltrative or invasive encapsulated follicular variant of papillary thyroid carcinoma: a review of 179 cases. Diagn Cytopathol 2017;45:533-41.
[CROSSREF]
23. Hirokawa M, Carney JA, Goellner JR, DeLellis RA, Heffess CS, Katoh R, et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 2002;26:1508-14.
[CROSSREF] [PUBMED]
24. Liu Z, Bychkov A, Jung CK, Hirokawa M, Sui S, Hong S, et al. Interobserver and intraobserver variation in the morphological evaluation of noninvasive follicular thyroid neoplasm with papillary-like nuclear features in Asian practice. Pathol Int 2019;69:202-10.
[CROSSREF] [PUBMED]
25. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336-40.
[CROSSREF] [PUBMED]
26. Kakudo K, Liu Z, Bychkov A, Jung CK. Thyroid FNA cytology, differential diagnoses and pitfalls. 2nd ed. Singapore: Springer; 2019. Chapter 21, Nuclear features of papillary thyroid carcinoma (BRAF-like tumors), noninvasive follicular thyroid neoplasm with papillary-like nuclear features (RAS-like tumors) and follicular adenoma/follicular thyroid carcinoma (RAS-like tumors). p. 173-9.
27. Ohba K, Mitsutake N, Matsuse M, Rogounovitch T, Nishino N, Oki Y, et al. Encapsulated papillary thyroid tumor with delicate nuclear changes and a KRAS mutation as a possible novel subtype of borderline tumor. J Pathol Transl Med 2019;53:136-41.
[CROSSREF] [PUBMED] [PMC]
28. Jung CK, Park SY, Kim JH, Kakudo K. New insights into classification and risk stratification of encapsulated thyroid tumors with a predominantly papillary architecture. J Pathol Transl Med 2020;54:197-203.
[CROSSREF] [PUBMED] [PMC]
29. Rosario PW. Noninvasive encapsulated papillary RAS-like thyroid tumor (NEPRAS) or encapsulated papillary thyroid carcinoma (PTC). J Pathol Transl Med 2020;54:263-4.
[CROSSREF] [PUBMED] [PMC]
30. Sambade C, Franssila K, Cameselle-Teijeiro J, Nesland J, Sobrinho-Simoes M. Hyalinizing trabecular adenoma: a misnomer for a peculiar tumor of the thyroid gland. Endocr Pathol 1991;2:83-91.
[CROSSREF] [PUBMED]
31. Nikiforova MN, Nikiforov YE, Ohori NP. GLIS rearrangements in thyroid nodules: a key to preoperative diagnosis of hyalinizing trabecular tumor. Cancer Cytopathol 2019;127:560-6.
[CROSSREF] [PUBMED]
32. Marchio C, Da Cruz Paula A, Gularte-Merida R, Basili T, Brandes A, da Silva EM, et al. PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. Mod Pathol 2019;32:1734-43.
[CROSSREF] [PUBMED] [PMC]
33. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676-90.
[CROSSREF] [PUBMED] [PMC]
34. Nikiforova MN, Nikitski AV, Panebianco F, Kaya C, Yip L, Williams M, et al. GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the thyroid gland. Thyroid 2019;29:161-73.
[CROSSREF] [PUBMED] [PMC]
35. Nath MC, Erickson LA. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. Adv Anat Pathol 2018;25:172-9.
[CROSSREF] [PUBMED]
36. Ho AS, Luu M, Barrios L, Chen I, Melany M, Ali N, et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma. JAMA Oncol 2020;6:706-13.
[CROSSREF] [PUBMED]
37. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
[CROSSREF] [PUBMED] [PMC]
38. Song E, Jeon MJ, Oh HS, Han M, Lee YM, Kim TY, et al. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma? Eur J Endocrinol 2018;179:135-42.
[CROSSREF] [PUBMED]
39. Limberg J, Ullmann TM, Stefanova D, Buicko JL, Finnerty BM, Zarnegar R, et al. Does aggressive variant histology without invasive features predict overall survival in papillary thyroid cancer?: a national cancer database analysis. Ann Surg 2019 Oct 9 [Epub].
https://doi.org/10.1097/SLA.00000-00000003632
.
[CROSSREF]
40. Jung CK. Papillary thyroid carcinoma variants with tall columnar cells. J Pathol Transl Med 2020;54:123.
[CROSSREF] [PUBMED] [PMC]
41. Ganly I, Ibrahimpasic T, Rivera M, Nixon I, Palmer F, Patel SG, et al. Prognostic implications of papillary thyroid carcinoma with tall-cell features. Thyroid 2014;24:662-70.
[CROSSREF] [PUBMED]
42. Wong KS, Higgins SE, Marqusee E, Nehs MA, Angell T, Barletta JA. Tall cell variant of papillary thyroid carcinoma: impact of change in WHO definition and molecular analysis. Endocr Pathol 2019;30:43-8.
[CROSSREF] [PUBMED]
43. Beninato T, Scognamiglio T, Kleiman DA, Uccelli A, Vaca D, Fahey TJ 3rd, et al. Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma. Surgery 2013;154:1331-6.
[CROSSREF] [PUBMED]
44. Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer 2015;22:419-29.
[CROSSREF] [PUBMED]
45. Vuong HG, Long NP, Anh NH, Nghi TD, Hieu MV, Hung LP, et al. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis. Endocr Connect 2018;7:R286-93.
[CROSSREF] [PUBMED] [PMC]
46. Bongers PJ, Kluijfhout WP, Verzijl R, Lustgarten M, Vermeer M, Goldstein DP, et al. Papillary thyroid cancers with focal tall cell change are as aggressive as tall cell variants and should not be considered as low-risk disease. Ann Surg Oncol 2019;26:2533-9.
[CROSSREF] [PUBMED]
47. Oh WJ, Lee YS, Cho U, Bae JS, Lee S, Kim MH, et al. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. Korean J Pathol 2014;48:201-8.
[CROSSREF] [PUBMED] [PMC]
48. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008;113:48-56.
[CROSSREF] [PUBMED]
49. Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck 2011;33:1052-9.
[CROSSREF] [PUBMED]
50. Shi X, Liu R, Basolo F, Giannini R, Shen X, Teng D, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 2016;101:264-74.
[CROSSREF] [PUBMED]
51. Villar-Taibo R, Peteiro-Gonzalez D, Cabezas-Agricola JM, Aliyev E, Barreiro-Morandeira F, Ruiz-Ponte C, et al. Aggressiveness of the tall cell variant of papillary thyroid carcinoma is independent of the tumor size and patient age. Oncol Lett 2017;13:3501-7.
[CROSSREF] [PUBMED] [PMC]
52. Enriquez ML, Baloch ZW, Montone KT, Zhang PJ, LiVolsi VA. CDX2 expression in columnar cell variant of papillary thyroid carcinoma. Am J Clin Pathol 2012;137:722-6.
[CROSSREF] [PUBMED]
53. Sujoy V, Pinto A, Nose V. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression. Thyroid 2013;23:714-9.
[CROSSREF] [PUBMED]
54. Yunta PJ, Ponce JL, Prieto M, Merino F, Sancho-Fornos S. The importance of a tumor capsule in columnar cell thyroid carcinoma: a report of two cases and review of the literature. Thyroid 1999;9:815-9.
[CROSSREF] [PUBMED]
55. Huang WT, Yang SF, Wang SL, Chan HM, Chai CY. Encapsulated columnar-cell carcinoma of the thyroid: a case report. Kaohsiung J Med Sci 2005;21:241-4.
[CROSSREF] [PUBMED]
56. Chen JH, Faquin WC, Lloyd RV, Nose V. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol 2011;24:739-49.
[CROSSREF] [PUBMED]
57. Ieni A, Barresi V, Cardia R, Licata L, Di Bari F, Benvenga S, et al. The micropapillary/hobnail variant of papillary thyroid carcinoma: a review of series described in the literature compared to a series from one southern Italy pathology institution. Rev Endocr Metab Disord 2016;17:521-7.
[CROSSREF] [PUBMED]
58. Kakudo K, Tang W, Ito Y, Mori I, Nakamura Y, Miyauchi A. Papillary carcinoma of the thyroid in Japan: subclassification of common type and identification of low risk group. J Clin Pathol 2004;57:1041-6.
[CROSSREF] [PUBMED] [PMC]
59. Bai Y, Kakudo K, Li Y, Liu Z, Ozaki T, Ito Y, et al. Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type. Cancer Sci 2008;99:1908-15.
[CROSSREF] [PUBMED]
60. Bai Y, Kakudo K, Nakamura M, Ozaki T, Li Y, Liu Z, et al. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma and periostin expression. Cancer Lett 2009;281:188-95.
[CROSSREF] [PUBMED]
61. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma: a clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 2010;34:44-52.
[CROSSREF] [PUBMED]
62. Liu Z, Kakudo K, Bai Y, Li Y, Ozaki T, Miyauchi A, et al. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition. J Clin Pathol 2011;64:325-9.
[CROSSREF] [PUBMED]
63. Asioli S, Erickson LA, Righi A, Lloyd RV. Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. Hum Pathol 2013;44:320-8.
[CROSSREF] [PUBMED]
64. Ambrosi F, Righi A, Ricci C, Erickson LA, Lloyd RV, Asioli S. Hobnail variant of papillary thyroid carcinoma: a literature review. Endocr Pathol 2017;28:293-301.
[CROSSREF] [PUBMED]
65. Lee YS, Kim Y, Jeon S, Bae JS, Jung SL, Jung CK. Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review. Int J Clin Exp Pathol 2015;8:7988-97.
[PUBMED] [PMC]
66. Teng L, Deng W, Lu J, Zhang J, Ren X, Duan H, et al. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma. Oncotarget 2017;8:22023-33.
[CROSSREF] [PUBMED] [PMC]
67. Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias-Santagata D, Faquin WC, et al. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid 2014;24:958-65.
[CROSSREF] [PUBMED] [PMC]
68. Wong KS, Chen TY, Higgins SE, Howitt BE, Lorch JH, Alexander EK, et al. A potential diagnostic pitfall for hobnail variant of papillary thyroid carcinoma. Histopathology 2020;76:707-13.
[CROSSREF] [PUBMED]
69. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007;31:1256-64.
[CROSSREF] [PUBMED]
70. Collini P, Mattavelli F, Pellegrinelli A, Barisella M, Ferrari A, Massimino M. Papillary carcinoma of the thyroid gland of childhood and adolescence: morphologic subtypes, biologic behavior and prognosis: a clinicopathologic study of 42 sporadic cases treated at a single institution during a 30-year period. Am J Surg Pathol 2006;30:1420-6.
[CROSSREF] [PUBMED]
71. LiVolsi VA, Abrosimov AA, Bogdanova T, Fadda G, Hunt JL, Ito M, et al. The Chernobyl thyroid cancer experience: pathology. Clin Oncol (R Coll Radiol) 2011;23:261-7.
[CROSSREF] [PUBMED]
72. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 2001;25:1478-84.
[CROSSREF] [PUBMED]
73. Tronko MD, Bogdanova TI, Komissarenko IV, Epstein OV, Oliynyk V, Kovalenko A, et al. Thyroid carcinoma in children and adolescents in Ukraine after the Chernobyl nuclear accident: statistical data and clinicomorphologic characteristics. Cancer 1999;86:149-56.
[CROSSREF] [PUBMED]
74. Ohashi R. Solid variant of papillary thyroid carcinoma: an under-recognized entity. Endocr J 2020;67:241-8.
[CROSSREF] [PUBMED]
75. Ohashi R, Kawahara K, Namimatsu S, Igarashi T, Sakatani T, Sugitani I, et al. Clinicopathological significance of a solid component in papillary thyroid carcinoma. Histopathology 2017;70:775-81.
[CROSSREF] [PUBMED]
76. Caplan RH, Wester S, Kisken AW. Diffuse sclerosing variant of papillary thyroid carcinoma: case report and review of the literature. Endocr Pract 1997;3:287-92.
[CROSSREF] [PUBMED]
77. Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, et al. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. Histopathology 2016;69:45-53.
[CROSSREF] [PUBMED]
78. Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol 2007;20:779-87.
[CROSSREF] [PUBMED]
79. Pillai S, Gopalan V, Smith RA, Lam AK. Diffuse sclerosing variant of papillary thyroid carcinoma: an update of its clinicopathological features and molecular biology. Crit Rev Oncol Hematol 2015;94:64-73.
[CROSSREF] [PUBMED]
80. Thompson LD, Wieneke JA, Heffess CS. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol 2005;16:331-48.
[CROSSREF] [PUBMED]
81. Koo JS, Hong S, Park CS. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid 2009;19:1225-31.
[CROSSREF] [PUBMED]
82. Fukushima M, Ito Y, Hirokawa M, Akasu H, Shimizu K, Miyauchi A. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 2009;33:958-62.
[CROSSREF] [PUBMED]
83. Malandrino P, Russo M, Regalbuto C, Pellegriti G, Moleti M, Caff A, et al. Outcome of the diffuse sclerosing variant of papillary thyroid cancer: a meta-analysis. Thyroid 2016;26:1285-92.
[CROSSREF] [PUBMED]
84. Kim HJ, Sung JY, Oh YL, Kim JH, Son YI, Min YK, et al. Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck 2014;36:1695-700.
[CROSSREF] [PUBMED]
85. Xu B, Ghossein R. Encapsulated thyroid carcinoma of follicular cell origin. Endocr Pathol 2015;26:191-9.
[CROSSREF] [PUBMED]
86. O’Neill CJ, Vaughan L, Learoyd DL, Sidhu SB, Delbridge LW, Sywak MS. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur J Surg Oncol 2011;37:181-5.
[CROSSREF] [PUBMED]
87. Cracolici V, Ritterhouse LL, Segal JP, Puranik R, Wanjari P, Kadri S, et al. Follicular thyroid neoplasms: comparison of clinicopathologic and molecular features of atypical adenomas and follicular thyroid carcinomas. Am J Surg Pathol 2020;44:881-92.
[CROSSREF] [PUBMED]
88. Maximo V, Sobrinho-Simoes M. Mitochondrial DNA ‘common’ deletion in Hurthle cell lesions of the thyroid. J Pathol 2000;192:561-2.
[CROSSREF] [PUBMED]
89. Bishop JA, Wu G, Tufano RP, Westra WH. Histological patterns of locoregional recurrence in Hürthle cell carcinoma of the thyroid gland. Thyroid 2012;22:690-4.
[CROSSREF] [PUBMED]
90. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol (Oxf) 2005;63:87-93.
[CROSSREF] [PUBMED]
91. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 2007;104:9001-6.
[CROSSREF] [PUBMED] [PMC]
92. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002;160:1857-65.
[CROSSREF] [PUBMED] [PMC]
93. Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. Clinical and molecular features of Hurthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 2015;100:55-62.
[CROSSREF] [PUBMED]
94. Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, et al. Integrated genomic analysis of Hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. Cancer Cell 2018;34:256-70.
[CROSSREF] [PUBMED] [PMC]
95. Jung CK, Kim Y, Jeon S, Jo K, Lee S, Bae JS. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors. Hum Pathol 2018;81:9-17.
[CROSSREF] [PUBMED]
96. Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid: a clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983;52:1849-55.
[CROSSREF] [PUBMED]
97. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 2006;106:1286-95.
[CROSSREF] [PUBMED]
98. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol 2010;23:1269-78.
[CROSSREF] [PUBMED]
99. Bai S, Baloch ZW, Samulski TD, Montone KT, LiVolsi VA. Poorly differentiated oncocytic (Hürthle cell) follicular carcinoma: an institutional experience. Endocr Pathol 2015;26:164-9.
[CROSSREF] [PUBMED]
100. Ziad el A, Ruchala M, Breborowicz J, Gembicki M, Sowinski J, Grzymislawski M. Immunoexpression of TTF-1 and Ki-67 in a coexistent anaplastic and follicular thyroid cancer with rare long-life surviving. Folia Histochem Cytobiol 2008;46:461-4.
[CROSSREF] [PUBMED]
101. Kakudo K, Wakasa T, Ohta Y, Yane K, Ito Y, Yamashita H. Prognostic classification of thyroid follicular cell tumors using Ki-67 labeling index: risk stratification of thyroid follicular cell carcinomas. Endocr J 2015;62:1-12.
[CROSSREF] [PUBMED]
102. Deeken-Draisey A, Yang GY, Gao J, Alexiev BA. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study. Hum Pathol 2018;82:140-8.
[CROSSREF] [PUBMED]
103. Dettmer M, Schmitt A, Steinert H, Haldemann A, Meili A, Moch H, et al. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am J Surg Pathol 2011;35:1866-72.
[CROSSREF] [PUBMED]
104. Wong KS, Lorch JH, Alexander EK, Marqusee E, Cho NL, Nehs MA, et al. Prognostic significance of extent of invasion in poorly differentiated thyroid carcinoma. Thyroid 2019;29:1255-61.
[CROSSREF] [PUBMED]
105. Ibrahimpasic T, Ghossein R, Shah JP, Ganly I. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid 2019;29:311-21.
[CROSSREF] [PUBMED] [PMC]
106. Bournaud C, Descotes F, Decaussin-Petrucci M, Berthiller J, de la Fouchardiere C, Giraudet AL, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Eur J Cancer 2019;108:41-9.
[CROSSREF] [PUBMED]
107. Xu B, Ghossein R. Poorly differentiated thyroid carcinoma. Semin Diagn Pathol 2020;37:243-7.
[CROSSREF] [PUBMED]
108. Keutgen XM, Sadowski SM, Kebebew E. Management of anaplastic thyroid cancer. Gland Surg 2015;4:44-51.
[PUBMED] [PMC]
109. Kuhn E, Ragazzi M, Ciarrocchi A, Torricelli F, de Biase D, Zanetti E, et al. Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study. Mod Pathol 2019;32:787-98.
[CROSSREF] [PUBMED]
110. Talbott I, Wakely PE Jr. Undifferentiated (anaplastic) thyroid carcinoma: practical immunohistochemistry and cytologic look-alikes. Semin Diagn Pathol 2015;32:305-10.
[CROSSREF] [PUBMED]
111. Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol 2011;42:1873-7.
[CROSSREF] [PUBMED]
112. Lai WA, Hang JF, Liu CY, Bai Y, Liu Z, Gu H, et al. PAX8 expression in anaplastic thyroid carcinoma is less than those reported in early studies: a multi-institutional study of 182 cases using the monoclonal antibody MRQ-50. Virchows Arch 2020;476:431-7.
[CROSSREF] [PUBMED]
113. Nakazawa T, Kondo T, Vuong HG, Odate T, Kawai M, Tahara I, et al. High expression of CD10 in anaplastic thyroid carcinomas. Histopathology 2018;73:492-9.
[CROSSREF] [PUBMED]
114. Oh EJ, Bychkov A, Cho H, Kim TM, Bae JS, Lim DJ, et al. Prognostic implications of CD10 and CD15 expression in papillary thyroid carcinoma. Cancers (Basel) 2020;12:1413.
[CROSSREF] [PMC]
115. Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 2020;30:1505-17.
[CROSSREF] [PUBMED]
116. Leeman-Neill RJ, Kelly LM, Liu P, Brenner AV, Little MP, Bogdanova TI, et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer 2014;120:799-807.
[CROSSREF] [PUBMED]
117. Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, et al. Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol 2016;29:985-95.
[CROSSREF] [PUBMED] [PMC]
118. Stevens TM, Kovalovsky AO, Velosa C, Shi Q, Dai Q, Owen RP, et al. Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. Mod Pathol 2015;28:1084-100.
[CROSSREF] [PUBMED]
119. Tirro E, Martorana F, Romano C, Vitale SR, Motta G, Di Gregorio S, et al. Molecular alterations in thyroid cancer: from bench to clinical practice. Genes (Basel) 2019;10:709.
[CROSSREF] [PMC]
120. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018;15:731-47.
[CROSSREF] [PUBMED] [PMC]